Startupsby GlyphWhy it ranks
How the rank works13signal of 100 · rising 3
- team of 10Team size · YC's directory+5.4
- acquiredOutcome · YC, program pages, Acquisitions+4
- went through YCProgram · this site+4
A sum of public facts, not a judgement and not investment advice.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCS23 | |
| Other | Active | YCW21 | |
| Other | Active | YCW21 | |
| AI | Active | YCS20 | |
| Other | Active | YCW24 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YCW24 | |
| Other | Active | YCW24 | |
| Other | Active | YCS21 | |
| Other | Active | YCW24 | |
| Other | Active | YCW24 |
Also from W22
All of W22About Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
- YC batch
- W22 · Winter 2022
- Status, per YC
- Acquired
- Category
- Other
- Team size
- 10
- Location
- San Francisco, CA, USA
- Checked
- 13h ago
YC tags: Synthetic Biology, Biotech, Healthcare, Therapeutics, Drug discovery
Engage Bio: questions
Which YC batch was Engage Bio in?
Engage Bio was in Y Combinator's Winter 2022 batch (W22).
Is Engage Bio still active?
Y Combinator lists Engage Bio as acquired.
Where is Engage Bio based?
Engage Bio lists San Francisco, CA, USA as its location on YC's directory.